Vaxart (NASDAQ:VXRT) Shares Cross Above Two Hundred Day Moving Average of $0.84

Vaxart, Inc. (NASDAQ:VXRT) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.84 and traded as high as $0.85. Vaxart shares last traded at $0.79, with a volume of 1,486,286 shares changing hands.

Analysts Set New Price Targets

Separately, Oppenheimer assumed coverage on Vaxart in a research note on Thursday, August 15th. They set an “outperform” rating and a $4.00 price objective for the company.

Vaxart Stock Performance

The business’s 50 day moving average price is $0.79 and its 200 day moving average price is $0.84. The firm has a market cap of $145.20 million, a price-to-earnings ratio of -1.55 and a beta of 0.65.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The business had revenue of $6.40 million for the quarter, compared to analysts’ expectations of $65.70 million. Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. During the same quarter in the prior year, the company posted ($0.16) EPS. Sell-side analysts anticipate that Vaxart, Inc. will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxart

Several large investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Vaxart during the 1st quarter worth approximately $20,000,000. Vanguard Group Inc. raised its position in shares of Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock valued at $10,984,000 after buying an additional 1,404,391 shares during the period. Millennium Management LLC lifted its holdings in Vaxart by 110.8% in the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after acquiring an additional 2,095,274 shares during the last quarter. Monaco Asset Management SAM purchased a new position in Vaxart in the second quarter worth approximately $402,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Vaxart during the second quarter worth $65,000. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.